1. Home
  2. ONC vs CVE Comparison

ONC vs CVE Comparison

Compare ONC & CVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • CVE
  • Stock Information
  • Founded
  • ONC 2010
  • CVE 2009
  • Country
  • ONC Switzerland
  • CVE Canada
  • Employees
  • ONC N/A
  • CVE N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • CVE Oil & Gas Production
  • Sector
  • ONC Health Care
  • CVE Energy
  • Exchange
  • ONC Nasdaq
  • CVE Nasdaq
  • Market Cap
  • ONC 26.9B
  • CVE 24.1B
  • IPO Year
  • ONC N/A
  • CVE N/A
  • Fundamental
  • Price
  • ONC $245.58
  • CVE $13.18
  • Analyst Decision
  • ONC Strong Buy
  • CVE Strong Buy
  • Analyst Count
  • ONC 7
  • CVE 4
  • Target Price
  • ONC $326.43
  • CVE $25.75
  • AVG Volume (30 Days)
  • ONC 368.4K
  • CVE 13.2M
  • Earning Date
  • ONC 05-07-2025
  • CVE 05-08-2025
  • Dividend Yield
  • ONC N/A
  • CVE 3.97%
  • EPS Growth
  • ONC N/A
  • CVE N/A
  • EPS
  • ONC N/A
  • CVE 1.05
  • Revenue
  • ONC $4,180,740,829.00
  • CVE $37,926,044,442.00
  • Revenue This Year
  • ONC $32.78
  • CVE N/A
  • Revenue Next Year
  • ONC $19.07
  • CVE N/A
  • P/E Ratio
  • ONC N/A
  • CVE $12.27
  • Revenue Growth
  • ONC 52.09
  • CVE 2.85
  • 52 Week Low
  • ONC $141.31
  • CVE $10.23
  • 52 Week High
  • ONC $287.88
  • CVE $21.08
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • CVE 51.63
  • Support Level
  • ONC N/A
  • CVE $12.88
  • Resistance Level
  • ONC N/A
  • CVE $13.83
  • Average True Range (ATR)
  • ONC 0.00
  • CVE 0.38
  • MACD
  • ONC 0.00
  • CVE -0.01
  • Stochastic Oscillator
  • ONC 0.00
  • CVE 24.18

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About CVE Cenovus Energy Inc

Cenovus Energy Inc is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 786 thousand barrels of oil equivalent per day in 2022. The company had upstream projects across Western Canada; crude oil production and natural gas and NGLs production offshore China and Indonesia. The downstream operations include upgrading and refining operations in Canada and the U.S., and commercial fuel operations across Canada.

Share on Social Networks: